By Editor • September 3, 2026 • 1 min read
Abivax, a promising French biotech firm, remains unacquired despite expectations of a $20 billion deal, leaving investors concerned.
Read moreBy Editor • September 2, 2026 • 1 min read
Trump's new drug pricing deals with biotech firms may not effectively reduce costs, primarily impacting Medicaid but exempting Medicare.
Read moreBy Editor • September 1, 2026 • 1 min read
The Trump administration's announcement of drug pricing deals raises significant unanswered questions about their implications.
Read moreBy Editor • August 31, 2026 • 1 min read
Trump announces new deals with nine drugmakers to ensure lower prices for U.S. patients and Medicaid programs.
Read moreBy Editor • August 14, 2026 • 1 min read
Formation Bio has appointed Michael Ehlers as chief scientific officer, previously CEO of Ascidian Therapeutics.
Read more
